Valuation dashboard for Abivax S.A. (ABVX) with P/E N/A, P/B 16.68, EV/EBITDA -22.5 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19.
Analysis Summary
Trailing-twelve-month margins: gross margin 153.1%, operating margin 119.5%, net margin 174.9%.
At $89.49 (closing price, November 4, 2026), ABVX has negative trailing earnings (P/E not meaningful) and an ROE of -85.88%. Market capitalisation stands at $7.8B.
Balance sheet quality for ABVX: debt-to-equity ratio of 0.00, current ratio of 5.97 over the last 12 months. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 16.68 |
| EV / EBITDA | -22.5 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| ABVX | Abivax S.A. | $7.8B | 16.68 | -85.9% | |
| SYRE | Spyre Therapeutics, Inc. | $9.1B | 32.59 | -29.8% | |
| RCUS | Arcus Biosciences, Inc. | $2.4B | 6.87 | -90.0% | |
| VRTX | Vertex Pharmaceuticals Incorporated | $139.2B | 35.33 | 6.66 | 20.1% |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $134.0B | 30.25 | 6.57 | 23.3% |
| MRNA | Moderna, Inc. | $103.2B | 14.63 | -39.2% | |
| REGN | Regeneron Pharmaceuticals, Inc. | $95.8B | 20.56 | 2.79 | 15.1% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $86.5B | 19.22 | 2.62 | 13.8% |
Price
| Price | $89.49 (closing price, November 4, 2026) |
| Market Cap | $7.8B |
| Exchange | NASDAQ |
| Country | FR |
Profitability
| Return on Equity | -85.88% |
| Return on Invested Capital | -60.98% |
| Return on Assets | -76.32% |
| Gross Margin | 153.15% |
| Operating Margin | 11,950.42% |
| Net Margin | 17,488.89% |
Related companies: SYRE · RCUS · VRTX · 0QZU.L · MRNA · REGN · 0R2M.L · ARGX
Explore sector: Healthcare · Biotechnology
More sections of ABVX: Overview · Financials · Estimates · Technical · Ownership
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks